ICAM1 and neoplasm: Results obtained in a flow cytometry-based kill assay with CD19+ target cells and a CD19xCD3 bsAb show that neither CD18 blockade nor combined blockade with CD54 antibodies (at 1 μg/mL) and CD18 antibodies (at 0.1 μg/mL or 0.01μg/mL) show any negative impact on tumor cell killing (Figure S6).